Eptinezumab for Pediatric Migraine
(REJOIN Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is eptinezumab safe for use in humans?
Eptinezumab, also known as Vyepti, is generally considered safe for preventing migraines in adults, with common mild side effects like nasal congestion and upper respiratory infections. It has been well tolerated in studies, even in patients with other health conditions like obesity and diabetes, but more research is needed to confirm its long-term safety.12345
How is the drug eptinezumab different from other migraine treatments?
Eptinezumab is unique because it is given as a quarterly infusion (injected directly into the bloodstream) and works quickly to prevent migraines by blocking a protein called CGRP, which is involved in causing migraines. This fast-acting infusion method sets it apart from other migraine treatments that may be taken more frequently or in different forms.23678
What data supports the effectiveness of the drug Eptinezumab for pediatric migraine?
Who Is on the Research Team?
Email contact via H. Lundbeck A/S
Principal Investigator
H. Lundbeck A/S
Are You a Good Fit for This Trial?
This trial is for children and adolescents aged 6 to 17 who suffer from chronic or episodic migraine and have completed a previous related study. They cannot join if they had severe reactions to the earlier treatment, significant liver test abnormalities, or other safety concerns as determined by the investigator.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive intravenous infusions of eptinezumab at Weeks 0, 12, and 24
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension
Participants continue receiving eptinezumab in an open-label format to assess long-term safety
What Are the Treatments Tested in This Trial?
Interventions
- Eptinezumab
Eptinezumab is already approved in United States for the following indications:
- Preventive treatment of migraine in adults
Find a Clinic Near You
Who Is Running the Clinical Trial?
H. Lundbeck A/S
Lead Sponsor
Charl van Zyl
H. Lundbeck A/S
Chief Executive Officer since 2023
Degree in Medical Biochemistry from the University of Cape Town, South Africa
Johan Luthman
H. Lundbeck A/S
Chief Medical Officer since 2019
MD from the University of Gothenburg, Sweden